| BCL high dose, mean ± SD | BCL low dose, mean ± SD | Placebo, mean ± SD | |
---|---|---|---|---|
KOOS change at T1 (difference between T1 and baseline) | N | 49 | 46 | 45 |
Global score | 35.2 ± 67.5 | 18.0 ± 57.6 | 7.9 ± 60.2 | |
Pain | 7.1 ± 17.5 | 4.8 ± 16.7 | 3.1 ± 13.9 | |
Symptoms | 6.7 ± 15.2 | 2.9 ± 13.6 | 1.7 ± 14.6 | |
Function in daily living (ADL) | 5.9 ± 19.6 | 4.0 ± 16.5 | 1.4 ± 13.2 | |
Function in sport and recreation (sport/rec) | 10.5 ± 18.0 | 4.2 ± 16.7 | 2.3 ± 15.4 | |
Knee-related quality of life (QoL) | 5.6 ± 14.8 | 3.1 ± 14.9 | − 0.2 ± 16.2 | |
KOOS change at T3 (difference between T3 and baseline) | N | 47 | 38 | 40 |
Global score | 56.3 ± 82.6 | 48. ± 73.1 | 42.1 ± 66.2 | |
Pain | 12.3 ± 19.4 | 12.8 ± 18.4 | 10.8 ± 16.5 | |
Symptoms | 10.0 ± 16.6 | 7.4 ± 16.0 | 7.5 ± 14.7 | |
Function in daily living (ADL) | 9.2 ± 19.5 | 10.3 ± 20.9 | 7.3 ± 14.6 | |
Function in sport and recreation (sport/rec) | 11.1 ± 20.5 | 9.6 ± 15.3 | 9.7 ± 17. 8 | |
Knee related quality of life (QoL) | 12.4 ± 20.3 | 9.2 ± 19.3 | 6.6 ± 16.8 |